Skip to main content
Journal cover image

Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

Publication ,  Journal Article
Schreiber, K; Giles, I; Costedoat-Chalumeau, N; Nelson-Piercy, C; Dolhain, RJ; Mosca, M; Förger, F; Fischer-Betz, R; Molto, A; Tincani, A ...
Published in: Lancet Rheumatology
September 1, 2023

Duke Scholars

Published In

Lancet Rheumatology

DOI

EISSN

2665-9913

Publication Date

September 1, 2023

Volume

5

Issue

9

Start / End Page

e501 / e506

Related Subject Headings

  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schreiber, K., Giles, I., Costedoat-Chalumeau, N., Nelson-Piercy, C., Dolhain, R. J., Mosca, M., … Andreoli, L. (2023). Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology, 5(9), e501–e506. https://doi.org/10.1016/S2665-9913(23)00215-1
Schreiber, K., I. Giles, N. Costedoat-Chalumeau, C. Nelson-Piercy, R. J. Dolhain, M. Mosca, F. Förger, et al. “Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases.” Lancet Rheumatology 5, no. 9 (September 1, 2023): e501–6. https://doi.org/10.1016/S2665-9913(23)00215-1.
Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology. 2023 Sep 1;5(9):e501–6.
Schreiber, K., et al. “Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases.” Lancet Rheumatology, vol. 5, no. 9, Sept. 2023, pp. e501–06. Scopus, doi:10.1016/S2665-9913(23)00215-1.
Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, Förger F, Fischer-Betz R, Molto A, Tincani A, Pasquier E, Marin B, Elefant E, Salmon J, Bermas BL, Sammaritano L, Clowse MEB, Chambers C, Buyon J, Inoue SA, Agmon-Levin N, Aguilera S, Emadi SA, Andersen J, Andrade D, Antovic A, Arnaud L, Christiansen AA, Avcin T, Badreh-Wirström S, Bertsias G, Bini I, Bobirca A, Branch W, Brucato A, Bultink I, Capela S, Cecchi I, Cervera R, Chighizola C, Cobilinschi C, Cuadrado MJ, Dey D, Etomi O, Espinosa G, Flint J, Fonseca JE, Fritsch-Stork R, Gerosa M, Glintborg B, Skorpen CG, Goulden B, Graversgaard C, Gunnarsson I, Gupta L, Hetland M, Hodson K, Hunt BJ, Isenberg D, Jacobsen S, Khamashta M, Levy R, Linde L, Lykke J, Meissner Y, Moore L, Morand E, Navarra S, Opris-Belinski D, Østensen M, Ozawa H, Perez-Garcia LF, Petri M, Pons-Estel GJ, Radin M, Raio L, Rottenstreich A, Ruiz-Irastorza G, Tunjić SR, Rygg M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou M, Troldborg A, Vinet E, Vojinovic J, Voss A, Wallenius M, Andreoli L. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology. 2023 Sep 1;5(9):e501–e506.
Journal cover image

Published In

Lancet Rheumatology

DOI

EISSN

2665-9913

Publication Date

September 1, 2023

Volume

5

Issue

9

Start / End Page

e501 / e506

Related Subject Headings

  • 3202 Clinical sciences